Teva Pharmaceutical Industries Limited (TEVA) Q4 2024 Earnings Conference Call Transcript

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q4 2024 Earnings Conference Call January 29, 2025 8:00 AM ET

Company Participants

Christopher Stevo – SVP, IR
Richard Francis – President & CEO
Eric Hughes – Head of R&D & Chief Medical Officer
Eli Kalif – CFO

Conference Call Participants

Umer Raffat – Evercore ISI
Jason Gerberry – Bank of America
David Amsellem – Piper Sandler
Balaji Prasad – Barclays
Ash Verma – UBS
Yifeng Liu – HSBC
Glen Santangelo – Jefferies
Chris Schulz – J.P. Morgan

Operator

Hello, and welcome to the Fourth Quarter and Full-Year 2024 Teva Pharmaceutical Industries Earnings Conference Call. My name is Alex, and I’ll be coordinating the call today. [Operator Instructions]

I’ll now hand it over to your host, Chris Stevo, SVP, Investor Relations. Please go ahead.

Christopher Stevo

Thank you, Alex. Good morning and good afternoon, everyone. I’d like to remind you briefly that we’re going to be making forward-looking statements on this call. Any statements we make are as of today only and we undertake no obligation to update these statements afterwards. And if you have any questions about forward-looking statements or other risk disclosures, please see our SEC filings under Forms 10-K and 10-Q.

And with that, let me turn it over to Richard.

Richard Francis

Thank you, Chris, and good morning, good afternoon everybody. Thank you for dialing in for the call. Really excited to talk to you today about the 2024 performance of Teva and the lookout for 2025.

So as usual, I’m going to go back to the strategy, the Pivot to Growth strategy, what we set out in 2023 and what we accomplished of this strategy in 2024. As you remember, it’s based on four pillars, deliver on our growth engines, step-up innovation, create a sustainable generics powerhouse, and focus the business. And I’m really pleased to say that we’ve made